← Leaderboards
Gideon Shapiro
Eragen Biosciences, Inc.
$959,639
Attributed
$959,639
Total exposure
7
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$959,639 · 7
By mechanism
R41$535,739 · 5
R44$307,400 · 1
R43$116,500 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Somatostatin”
- Norman Wolmark · Nsabp Foundation, Inc.$52,338,276
- Alan D Cherrington · Vanderbilt University$12,498,973
- Jorge J Palop · J. David Gladstone Institutes$10,746,653
- Johannes D Veldhuis · University Of Virginia Charlottesville$9,450,586
- Nicholas C. Brecha · University Of California Los Angeles$8,938,423
- Gordon J Fishell · Harvard Medical School$8,724,508
Research focus
SomatostatinDrug Design /Synthesis /ProductionStimulant /AgonistChemical SynthesisLaboratory RatHigh Performance Liquid ChromatographyDrug Screening /EvaluationNeuropeptide ReceptorStereoisomerReceptor ExpressionPharmacokineticsMass SpectrometryReceptor BindingDiabetic RetinopathyHydropathyCombinatorial ChemistryBiotherapeutic AgentCho CellsImidazolidoneBiotechnologyAnticonvulsantsHistopathologyChemical Structure FunctionEye Disorder Chemotherapy
Grant awards (7)
Ocular Delivery of Non-Peptide Somatostatin Agonists$134,820
R41 · FY2004 · EY
Non-Peptide Somatostatin Agonist Analgesics$99,567
R41 · FY2004 · NS
Somatostatin Mimetics as Novel Anti-Epileptic Drugs$101,352
R41 · FY2003 · NS
Nonpeptide Somatostatin Agonists for Retinopathy$100,000
R41 · FY2003 · EY
Chiral CE for Non Peptide Somatostatin Drugs$100,000
R41 · FY2003 · DK
IN VITRO SELECTION OF FUNCTIONALIZED DNA APTAMERS$307,400
R44 · FY2000 · GM
EXTENDING THE SCOPE OF PNA WITH NON-STANDARD BASE PAIRS$116,500
R43 · FY2000 · GM